300519.SZ
新光药业
SZSE · Healthcare · C 制造业 · CN
CNY 14.08
−1.47%Year over year
Reported trailing growth
- Revenue
- +0.1%
- EBITDA
- —
- EBIT
- +13.7%
- EPS
- +7.0%
- Free cash flow
- +42.2%
- Operating cash flow
- +39.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -8.9%
- EBITDA
- -17.3%
- EBIT
- -20.0%
- Net income
- -20.7%
- EPS
- -20.6%
- Free cash flow
- -15.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026